Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tot Biopharm Opens New Biologics Facility in Suzhou

publication date: Jun 21, 2018

Tot Biopharm, a Suzhou oncology company, completed a monoclonal antibodies (mAb) manufacturing facility. The 13,000 square meter site will have a capacity of 16,000L when it is completely built out. Tot will use the plant for its own portfolio of oncology drugs as well as offering CDMO services to other biopharmas. The facility will offer upstream R&D, pilot-scale production, clinical trial-scale drug manufacturing and commercial production. Tot said the plant will produce both biologic drugs and small molecular drugs at commercial scale. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital